ITRMF (Iterum Therapeutics) Total Liabilities: $39.88 Mil (As of Sep. 2025)


What is Iterum Therapeutics Total Liabilities?

Iterum Therapeutics ITRMF +18.86% Total Liabilities is $39.88 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 was $39.88 Mil.

Iterum Therapeutics's quarterly Total Liabilities increased from Mar. 2025 ($35.53 Mil) to Jun. 2025 ($37.90 Mil) and increased from Jun. 2025 ($37.90 Mil) to Sep. 2025 ($39.88 Mil).

Iterum Therapeutics's annual Total Liabilities declined from Dec. 2022 ($38.83 Mil) to Dec. 2023 ($32.66 Mil) but then increased from Dec. 2023 ($32.66 Mil) to Dec. 2024 ($48.68 Mil).

Iterum Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Total Liabilities Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 83.35 41.28 38.83 32.66 48.68

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.43 48.68 35.53 37.90 39.88

Iterum Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Iterum Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.605+(31.071+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=48.68

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=44.595--4.081
=48.68

Iterum Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.43+(33.454+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=39.88

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=32.503--7.381
=39.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $39.88 Mil mean?
Iterum Therapeutics (ITRMF) has a Total Liabilities of $39.88 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' Total Liabilities too high?
Iterum Therapeutics' current Total Liabilities is $39.88 Mil.
How does Iterum Therapeutics' Total Liabilities compare to ENSC and PPCB?
Iterum Therapeutics' Total Liabilities of $39.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Iterum Therapeutics and its competitors. Iterum Therapeutics's current Total Liabilities is $39.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Total Liabilities of $39.88 Mil. The current Total Liabilities is $39.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Total Liabilities is $39.88 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.